Profectus BioSciences to conduct proof-of-concept studies with its rVSV vector technology
Links shared publicly online about this topic.
- 1,796total visits
Profectus BioSciences to conduct proof-of-concept studies with its rVSV vector technology
Profectus BioSciences, Inc. (Profectus), a clinical stage biopharmaceutical company focused on the development of novel vaccine candidates for serious chronic infections, announced today it has entered into a research collaboration agreement with the PATH Malaria Vaccine Initiative (MVI) to conduct proof-of-concept studies with its proprietary, recombinant vesicular stomatitis virus (rVSV) vector technology as a preventative malaria vaccine.
View full resource at news-medical.net
Tags: Vaccination, Infection, Malaria, Vaccine
Most Recently Shared on August 26, 2009 at 8:05 am By:
Malaria News: Profectus BioSciences to conduct proof-of-concept studies with its rVSV vector techno.. http://bit.ly/JZvHn
Advertisement
